A detailed history of Vanguard Personalized Indexing Management, LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Personalized Indexing Management, LLC holds 6,086 shares of ALNY stock, worth $1.53 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
6,086
Previous 6,390 4.76%
Holding current value
$1.53 Million
Previous $1.22 Million 25.67%
% of portfolio
0.02%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 09, 2024

SELL
$146.51 - $198.2 $44,539 - $60,252
-304 Reduced 4.76%
6,086 $909,000
Q4 2023

Feb 07, 2024

BUY
$151.41 - $196.57 $99,173 - $128,753
655 Added 11.42%
6,390 $1.22 Million
Q3 2023

Nov 08, 2023

SELL
$170.77 - $211.65 $106,389 - $131,857
-623 Reduced 9.8%
5,735 $1.02 Million
Q2 2023

Jul 28, 2023

BUY
$185.01 - $212.05 $10,915 - $12,510
59 Added 0.94%
6,358 $1.21 Million
Q1 2023

May 10, 2023

SELL
$182.66 - $235.53 $53,519 - $69,010
-293 Reduced 4.44%
6,299 $1.26 Million
Q4 2022

Feb 10, 2023

BUY
$185.53 - $241.31 $134,694 - $175,191
726 Added 12.38%
6,592 $1.57 Million
Q3 2022

Nov 14, 2022

BUY
$138.54 - $232.0 $193,678 - $324,336
1,398 Added 31.29%
5,866 $1.17 Million
Q2 2022

Aug 09, 2022

BUY
$120.42 - $169.29 $33,115 - $46,554
275 Added 6.56%
4,468 $652,000
Q1 2022

May 16, 2022

BUY
$127.18 - $173.91 $165,842 - $226,778
1,304 Added 45.14%
4,193 $685,000
Q4 2021

Feb 23, 2022

BUY
$159.56 - $209.29 $69,887 - $91,669
438 Added 17.87%
2,889 $490,000
Q3 2021

Nov 09, 2021

BUY
$169.75 - $207.73 $37,684 - $46,116
222 Added 9.96%
2,451 $463,000
Q2 2021

Aug 11, 2021

BUY
$128.63 - $176.89 $286,716 - $394,287
2,229 New
2,229 $378,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.9B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Vanguard Personalized Indexing Management, LLC Portfolio

Follow Vanguard Personalized Indexing Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Personalized Indexing Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Personalized Indexing Management, LLC with notifications on news.